Verastem Inc (VSTM)

3.59
0.01 0.28
NASDAQ : Health Care
Prev Close 3.58
Open 3.60
Day Low/High 3.37 / 3.64
52 Wk Low/High 1.05 / 8.07
Volume 421.85K
Avg Volume 964.90K
Exchange NASDAQ
Shares Outstanding 36.99M
Market Cap 132.06M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Verastem Reports Phase 2 Long-Term Follow-Up Data For Duvelisib In Patients With Double-Refractory Follicular Lymphoma And Small Lymphocytic Lymphoma At The 22nd Congress Of The European Hematology Association

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the presentation of long-term follow-up data from the DYNAMO™...

Verastem To Present Long-Term Follow-Up Data From The DYNAMO™ Study At The 14th International Conference On Malignant Lymphoma

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced long-term follow-up data from the DYNAMO™ study, which met its...

Verastem To Present At The Jefferies 2017 Global Healthcare Conference

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that the company will present at the Jefferies 2017 Global...

Verastem Announces Duvelisib Data Presentations At The 22nd Congress Of The European Hematology Association

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced an abstract featuring long-term follow up data from the DYNAMO®...

Verastem Reports First Quarter 2017 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today reported financial results for the first quarter ended March 31, 2017 and...

Verastem Announces Long Term Follow-up Data From The DYNAMO Study Selected For Oral Presentation At The 14th International Conference On Malignant Lymphoma

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that an abstract describing long term follow-up data from the...

Verastem Appoints Eric K. Rowinsky To The Board Of Directors

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced the appointment of Eric K.

Verastem To Present At The 16th Annual Needham Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 16 th Annual Needham Healthcare Conference on Tuesday, April 4 th at 3:00 p.

Data On Verastem's Focal Adhesion Kinase Inhibitor Defactinib Presented At The 2017 American Association For Cancer Research Annual Meeting

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced the oral presentation of data for its lead focal adhesion kinase (FAK) inhibitor, defactinib, by the Company's...

Verastem Reports Year-End 2016 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the year ended December 31, 2016, and also provided an overview of certain corporate...

Verastem To Host Conference Call On March 23rd To Discuss Fourth Quarter And Full-Year 2016 Financial Results And Recent Highlights

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the Company will host a conference call and webcast on Thursday, March 23, 2017 at 4:30 p.

Verastem To Present At The Oppenheimer 27th Annual Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27 th Annual Healthcare Conference on Tuesday, March 21 st at 2:10...

Verastem To Present At The 29th Annual ROTH Conference

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 29 th Annual ROTH Conference on Monday, March 13 th at 4:00 p.

Verastem To Present At 19th Annual BIO CEO & Investor Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the 19 th Annual BIO CEO & Investor Conference on Tuesday, February 14 th at...

Groundhog Day Arrives Early

Has anybody seen Bill Murray hanging around the S&P?

Verastem Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer

Verastem Announces Dosing Of First Patient In Combination Trial Of Defactinib And Avelumab In Patients With Ovarian Cancer

Verastem, Inc., (NASDAQ:VSTM) today announced dosing of the first patient in a new clinical trial evaluating avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's...

Verastem Announces Executive Leadership Appointments And Changes

Verastem Announces Executive Leadership Appointments And Changes

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced that Hagop Youssoufian, MSc, MD, has been appointed Head of Hematology and Oncology Development.

Verastem Presents Phase 2 DYNAMO® Clinical Data At ASH 2016 Annual Meeting

Verastem Presents Phase 2 DYNAMO® Clinical Data At ASH 2016 Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the presentation of results from the DYNAMO® study, a Phase 2 clinical trial evaluating the safety and efficacy...

Verastem Reports Third Quarter 2016 Financial Results

Verastem Reports Third Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the third quarter ended September 30, 2016, and also provided an overview of certain corporate...

Verastem Announces Presentations At ASH Annual Meeting

Verastem Announces Presentations At ASH Annual Meeting

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that new data for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and...

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem Licenses Duvelisib From Infinity Pharmaceuticals

Verastem, Inc. (NASDAQ:VSTM) and Infinity Pharmaceuticals, Inc.

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

Cancer Research UK, MSD And Verastem Collaborate To Trial New Combination Of Immunotherapy Drugs

CANCER RESEARCH UK has today (Friday) announced its first cross-company deal as part of its Experimental Cancer Medicine Centre (ECMC) Combinations Alliance.

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem To Present At Rodman & Renshaw 18th Annual Global Investment Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday,...

Verastem Reports Second Quarter 2016 Financial Results

Verastem Reports Second Quarter 2016 Financial Results

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today reported financial results for the second quarter ended June 30, 2016, and also provided an overview of certain corporate...

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem To Present At Cantor Fitzgerald's 2nd Annual Healthcare Conference

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at Cantor Fitzgerald's 2nd Annual Healthcare Conference on Wednesday, July 13th at...

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Study Published In Nature Medicine Highlights Potential Role Of FAK Inhibition In Pancreatic Cancer

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced the publication of preclinical research in the journal Nature Medicine by the Company's researchers and scientific...

Verastem Announces Changes To Its Board Of Directors

Verastem Announces Changes To Its Board Of Directors

Verastem, Inc. (NASDAQ: VSTM), focused on discovering and developing drugs to treat cancer, today announced several changes to the Company's Board of Directors.

Verastem To Present At Upcoming Investor Conferences

Verastem To Present At Upcoming Investor Conferences

Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the following upcoming investor conferences: The Jefferies 2016...